Showing 1 - 10 of 821
Debates over whether and when to recommend screening for a potential disease focus on the causal impact of screening for a typical individual covered by the recommendation, who may differ from the typical individual who responds to the recommendation. We explore this distinction in the context...
Persistent link: https://www.econbiz.de/10012864479
Persistent link: https://www.econbiz.de/10012108873
Persistent link: https://www.econbiz.de/10012102577
Debates over whether and when to recommend screening for a potential disease focus on the causal impact of screening for a typical individual covered by the recommendation, who may differ from the typical individual who responds to the recommendation. We explore this distinction in the context...
Persistent link: https://www.econbiz.de/10012480108
We present a simple graphical framework to illustrate the potential welfare gains from a “top-up” health insurance policy requiring patients to pay the incremental price for more expensive treatment options. We apply this framework to breast cancer treatments, where lumpectomy with radiation...
Persistent link: https://www.econbiz.de/10013052496
Persistent link: https://www.econbiz.de/10010366948
Persistent link: https://www.econbiz.de/10010386210
Persistent link: https://www.econbiz.de/10011448678
Medical technologies can target care to patients identified through screening, raising questions of how broadly to screen for potential use. We explore this empirically in the context of a non-invasive prenatal screening, cfDNA, which is used to target a more costly invasive test that elevates...
Persistent link: https://www.econbiz.de/10013462717
Persistent link: https://www.econbiz.de/10013464094